(0.32%) 5 116.38 points
(0.30%) 38 355 points
(0.37%) 15 987 points
(-0.95%) $83.05
(5.36%) $2.03
(0.32%) $2 354.80
(0.46%) $27.66
(4.15%) $960.35
(-0.27%) $0.932
(-0.45%) $10.98
(-0.58%) $0.796
(1.63%) $93.37
@ €88.00
発行日: 29 4月 2024 @ 22:33
リターン: 1.08%
前回のシグナル: 4月 27 - 01:27
前回のシグナル:
リターン: 0.77 %
Live Chart Being Loaded With Signals
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer...
Stats | |
---|---|
本日の出来高 | 195 821 |
平均出来高 | 590 212 |
時価総額 | 21.15B |
EPS | €0 ( 2024-03-20 ) |
次の収益日 | ( €-0.410 ) 2024-05-06 |
Last Dividend | €2.11 ( 2022-06-02 ) |
Next Dividend | €0 ( N/A ) |
P/E | 21.64 |
ATR14 | €2.51 (2.83%) |
ボリューム 相関
BioNTech SE 相関
10 最も正の相関 | |
---|---|
VERB | 0.95 |
OPINL | 0.946 |
BNGO | 0.944 |
VRAY | 0.944 |
AUDC | 0.942 |
NESR | 0.939 |
EGBN | 0.939 |
CNXC | 0.938 |
MAGS | 0.938 |
AGIL | 0.938 |
10 最も負の相関 | |
---|---|
XPDB | -0.94 |
ITAQ | -0.939 |
SWAV | -0.937 |
ROCL | -0.935 |
ATEC | -0.934 |
FTPA | -0.932 |
TIOA | -0.931 |
ROC | -0.931 |
CBRG | -0.93 |
BRIVU | -0.929 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
BioNTech SE 相関 - 通貨/商品
BioNTech SE 財務諸表
Annual | 2023 |
収益: | €3.82B |
総利益: | €3.22B (84.29 %) |
EPS: | €3.79 |
FY | 2023 |
収益: | €3.82B |
総利益: | €3.22B (84.29 %) |
EPS: | €3.79 |
FY | 2022 |
収益: | €17.31B |
総利益: | €12.78B (73.82 %) |
EPS: | €38.08 |
FY | 2021 |
収益: | €18.98B |
総利益: | €15.12B (79.66 %) |
EPS: | €40.63 |
Financial Reports:
No articles found.
BioNTech SE Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
First Dividend | €2.11 | 2022-06-02 |
Last Dividend | €2.11 | 2022-06-02 |
Next Dividend | €0 | N/A |
Payout Date | 2022-06-17 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | €2.11 | -- |
Avg. Dividend % Per Year | 0.15% | -- |
Score | 1.89 | -- |
Div. Sustainability Score | 9.73 | |
Div.Growth Potential Score | 2.39 | |
Div. Directional Score | 6.06 | -- |
Year | Amount | Yield |
---|---|---|
2022 | €2.11 | 0.91% |
2023 | €0 | 0.00% |
2024 | €0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.244 | 1.500 | 5.13 | 7.69 | [0 - 0.5] |
returnOnAssetsTTM | 0.0404 | 1.200 | 8.65 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0464 | 1.500 | -0.596 | -0.894 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 9.43 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 9.12 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 5.63 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.00952 | -1.500 | 9.84 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 5.58 | 1.000 | 9.04 | 9.04 | [3 - 30] |
operatingCashFlowPerShareTTM | 22.59 | 2.00 | 2.47 | 4.94 | [0 - 30] |
freeCashFlowPerShareTTM | 19.63 | 2.00 | 0.186 | 0.373 | [0 - 20] |
debtEquityRatioTTM | 0.0108 | -1.500 | 9.96 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.527 | 1.000 | 4.54 | 4.54 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.181 | 1.000 | 8.38 | 8.38 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 24.52 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.166 | 0.800 | -2.23 | -1.781 | [0.5 - 2] |
Total Score | 9.73 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 20.77 | 1.000 | 8.00 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0464 | 2.50 | -0.383 | -0.894 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 19.63 | 2.00 | 3.46 | 0.373 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 22.59 | 2.00 | 2.47 | 4.94 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 1.406 | 1.000 | 10.00 | 0 | [0.1 - 0.5] |
Total Score | 2.39 |
BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。